EnviroMetal Technologies Inc
6.12.2021 14:32:22 CET | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / December 6, 2021 / EnviroMetal Technologies Inc. ("EnviroMetal" or the "Company"), (CSE: ETI) (OTCQX: EVLLF) (FSE: 7N2) is pleased to report positive results of test work performed for P2 Gold Inc. ("P2") (TSX-V: PGLD) on mineralized material from P2's gold-copper Gabbs Project located on the Walker-Lane Trend in Nevada.
The test work was undertaken to determine the gold recovery potential and leach efficiency of EnviroMetal's patented eco-friendly formula to recover gold from the Gabbs Project.
Two gold-copper samples from the Gabbs Project were received at the EnviroMetal laboratory in Burnaby, BC and subsequently sent to a certified third-party lab for crushing, splitting, and assaying. EnviroMetal then processed the two samples using its proprietary lixiviant (leach solution). After 24 hours of processing, the calculated gold recoveries for both samples were approximately 90% as outlined in Tables 1 and 2 below.
Table 1: EnviroMetal Leach of Sample 1: Assayed Head Grade 0.72 g/t Au
Test Number | Calculated Head (g/t Au) | Residue | 24hr Gold | Reagent Concentration | |||||
Salt A | Salt B | Salt C | Other | ||||||
GR101 | 0.95 | 0.12 | 88.4 | Low | Low | Low | 0.0 | ||
GR102 | 1.18 | 0.12 | 90.5 | Low | 0.0 | 0.0 | Low | ||
Table 2: EnviroMetal Leach of Sample 2: Assayed Head Grade 1.45 g/t Au
Test Number | Calculated Head (g/t Au) | Residue | 24hr Gold | Reagent Concentration | |||||
Salt A | Salt B | Salt C | Other | ||||||
GR201 | 1.09 | 0.12 | 89.7 | Low | Low | Low | 0.0 | ||
GR202 | 1.25 | 0.19 | 85.6 | Low | 0.0 | 0.0 | Low | ||
Joe Ovsenek, President and CEO of P2 Gold commented: "We decided to investigate the use of EnviroMetal's eco-friendly gold extraction solutions for our Gabbs Project because of its record of extracting gold for other projects. With gold recoveries of approximately 90% for the Gabbs samples, the initial test work was definitely a success. Given these encouraging initial results, we intend to evaluate EnviroMetal's process as an alternative for gold recovery as we advance engineering for the Gabbs Project."
About P2 Gold
P2 Gold is a mineral exploration and development company focused on advancing precious metals discoveries and acquisitions in the western United States and British Columbia.
About EnviroMetal Technologies Inc.
EnviroMetal Technologies is engaged in the development and commercialization of environmentally-friendly formulas and technologies for the treatment of materials in the primary and secondary metals industries. Using its proprietary non-cyanide, water-based, neutral pH treatment process EnviroMetal extracts precious metals from ores, concentrates, and electronic waste ("E-Waste").
Backed by the momentum of a first-class staff of scientists and engineers, tens of thousands of individual tests and assays, independent validations, and tens of thousands of hours in research and development, EnviroMetal's technology is emerging as a potential new eco-friendly standard for the hydrometallurgical extraction of precious metals in both the mining and E-Waste industries. For more information please visit: https://EnviroMetal.com
Forward-Looking Statements
This News Release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and the United States securities legislation. Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continues," "estimates," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking information may include, but is not limited to, information concerning our Research and Development activities, the accuracy of our capital and operating cost estimates; production and processing estimates; the results, the adequacy of EnviroMetal's financial resources, and timing of development of ongoing research and development projects, costs and timing of future revenues or profits and adequacy of financial resources. Wherever possible, words such as "plans", "expects", "projects", "assumes", "budget", "strategy", "scheduled", "estimates", "forecasts", "anticipates", "believes", "intends", "targets" and similar expressions or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative forms of any of these terms and similar expressions, have been used to identify forward-looking statements and information. Statements concerning future revenue or earnings estimates may also be deemed to constitute forward-looking information. Any statements that express or involve discussions concerning predictions, expectations, beliefs, plans, projections, objectives, assumptions, or future events or performance are not statements of historical fact and may be forward-looking information. Forward-looking information is subject to a variety of known and unknown risks, uncertainties, and other factors that could cause actual events or results to differ from those expressed or implied by the forward-looking information. Forward-looking information is based on the expectations and opinions of EnviroMetal's management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise. We do not assume any obligation to update forward-looking information, whether as a result of new information, future events, or otherwise, other than as required by applicable law. For the reasons set forth above, prospective investors should not place undue reliance on forward-looking information. The CSE has not approved or disapproved of the information contained herein.
Contact Information :
Jason Leikam
VP Corporate Development
EnviroMetal Technologies Inc.
(604) 428-2400 x. 104
SOURCE: EnviroMetal Technologies Inc
View source version on accesswire.com:
https://www.accesswire.com/676130/EnviroMetal-Reports-High-Gold-Recoveries-in-Tests-for-P2-Golds-Gabbs-Project
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 20265.2.2026 12:00:00 CET | Press release
Datavault AI signed $49M of Tokenization and Technology Licensing agreements in Q4'25 that impact FY2025 and FY2026 Revenue. Revenue: Datavault AI expects at least $30 million in revenue for FY2025, compared to $2.7 million in FY2024. This represents an increase of more than 1,000% growth in our revenue over 2024. The Company continues to expand to drive substantial near- and long-term accretion to our cash flows and earnings with a revenue target for 2026 of at least $200 million. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / February 5, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies, today issued a letter from Nathaniel Bradley, its Chief Executive Officer, to its stockholders highlighting the Company's accomplishments in 2025 and its outlook for 2026. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Dear Datavault AI Stockholders, I would like t
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica
Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release
OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to
Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release
CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a
Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom